Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348581 | 0.84 | LMNA (0.67) | ALDH1A1NPC1RAB9ATP53KDM4E | |
| SCHEMBL8254073 | 0.83 | ALDH1A1 (0.74) | ALDH1A1TSHRNPC1RAB9ATP53 | |
| SCHEMBL4931794 | 0.82 | SIGMAR1 (0.75) | TSHRPOLBKMT2ALMNASIGMAR1 | |
| SCHEMBL8529470 | 0.82 | ALDH1A1 (1.00) | ALDH1A1TSHRNPC1RAB9ATP53 | |
| SCHEMBL12717312 | 0.82 | ALDH1A1 (0.71) | ALDH1A1TSHRNPC1RAB9ATP53 | |
| SCHEMBL2250410 | 0.81 | HRH3 (0.74) | ALDH1A1POLBSMN1; SMN2KDM4EHRH3 | |
| SCHEMBL20210251 | 0.81 | HRH3 (0.67) | ALDH1A1POLBSMN1; SMN2KDM4EKMT2A | |
| SCHEMBL5366249 | 0.81 | GAA (0.62) | ALDH1A1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4555241 | 0.80 | ALDH1A1 (0.60) | ALDH1A1TSHRNPC1RAB9ATP53 | |
| SCHEMBL2234365 | 0.80 | ALDH1A1 (0.69) | ALDH1A1TSHRNPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2021-11-25 | — | — | US | disclosed |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. | 2020-11-12 | — | — | US | disclosed |
| CN-104693193-B | Aryl methoxy isoindoline derivative and composition and their application method including it | 细胞基因公司 | 2018-09-18 | — | — | CN | disclosed |
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | HEPALINK (HONG KONG) LIMITED (HK) | 2018-04-19 | — | — | US | disclosed |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2016-04-21 | — | — | US | disclosed |
| US-9199990-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2015-12-01 | — | — | US | disclosed |
| CN-104693193-A | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORP | 2015-06-10 | — | — | CN | disclosed |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (US) | 2015-03-12 | — | — | US | disclosed |
| CN-102822165-B | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same | CELGENE CORP | 2015-02-25 | — | — | CN | disclosed |
| US-8889698-B2 | Compounds for the prevention and treatment of cardiovascular diseases | RESVERLOGIX CORP. (CA) | 2014-11-18 | — | — | US | disclosed |
| EP-2118074-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2009-11-18 | — | — | EP | disclosed |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | HEPALINK (HONG KONG) LIMITED (HK) | 2008-08-07 | — | — | US | disclosed |
| WO-2008092231-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | RESVERLOGIX CORP. (CA) | 2008-08-07 | — | — | WO | disclosed |
| EP-1501828-B1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | SERONO LAB (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-7314878-B2 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or CNS disorders | LABORATORIES SERONO SA (CH) | 2008-01-01 | — | — | US | disclosed |
| CN-1310911-C | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2007-04-18 | — | — | CN | disclosed |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-11-24 | — | — | US | disclosed |
| CN-1662528-A | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | CN | disclosed |
| EP-1501828-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | Applied Research Systems ARS Holding N.V. (AN) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003091249-A1 | PIPERAZINE BENZOTHIAZOLES AS AGENTS FOR THE TREATMENT OF CEREBRAL ISCHEMIC DISORDERS OR CNS DISORDERS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104245-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885TSHR 3859/4885NPC1 42/4885 |
| US-20210361656-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885TSHR 3859/4885NPC1 42/4885 |
| US-20200352946-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885TSHR 3859/4885NPC1 42/4885 |
| US-20160106750-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885TSHR 3859/4885NPC1 42/4885 |
| US-20150072955-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES | APOB, HDLBP, FABP3 | ALDH1A1 548/4885TSHR 3859/4885NPC1 42/4885 |
| US-20050261304-A1 | Piperazine benzothiazoles as agents for the treatment of cerebral ischemic disorders or cns disorders | PRDX5, PIR, GRIK5 | ALDH1A1 474/4885TSHR 3099/4885NPC1 960/4885 |
| US-20080188467-A1 | To regulate the expression of apolipoprotein A-I; atherosclerosis; improved pharmacological properties; 3-(4-hydroxy-3,5-dimethylphenyl)-6,8-dimethoxyisoquinolin-1(2H)-one; to reduce cholesterol levels; agonists | APOB, LDLR, APOL1 | ALDH1A1 1784/4885TSHR 2704/4885NPC1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.